Targeting specific mutations to treat a genetic muscle disorder
Allele Specific Knockdown for LGMDD1
This study is working on a new treatment for people with limb girdle muscular dystrophy D1, a muscle disorder caused by a gene problem, by targeting the harmful version of the gene while keeping the healthy part intact, to help improve muscle function and ease symptoms.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-11059246 on NIH RePORTER |
What this research studies
This research focuses on developing new therapies for limb girdle muscular dystrophy D1 (LGMDD1), a genetic muscle disorder caused by mutations in the DNAJB6 gene. The approach involves selectively knocking down the harmful mutant form of DNAJB6 while preserving the normal gene function, which is crucial for muscle health. By using advanced gene therapy techniques, the researchers aim to create a treatment that can alleviate the symptoms of this debilitating condition. This project seeks to address a significant gap in treatment options for patients with dominant muscular dystrophies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with limb girdle muscular dystrophy D1 caused by mutations in the DNAJB6 gene.
Not a fit: Patients with other forms of muscular dystrophy or those without DNAJB6 mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to effective therapies for patients suffering from LGMDD1, improving their quality of life.
How similar studies have performed: While gene therapy for muscular dystrophies is an emerging field, this specific approach targeting dominant mutations is novel and has not been extensively tested in previous studies.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Findlay, Andrew — Washington University
- Study coordinator: Findlay, Andrew
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.